• Verification code
  • Optimal Prices
    Buying products on this site guarantees the best price
  • Flexible Batches
    Flexible batch size to meet different needs of global customers
  • Prompt Delivery
    Warehouses in multiple cities to ensure timely delivery
  • Quality Assurance
    Strict process parameter control to ensure product quality
  • One-to-one Customization
    One-to-one custom synthesis for special structural needs

Cabotegravir-[13C,d5]

General Information
Catalog: BLP-002125
Molecular Formula: C18[13C]H12D5F2N3O5
Molecular Weight: 411.38
Chemical Structure
Cabotegravir-[13C,d5]
Description Cabotegravir-[13C,d5], is the labelled analogue of Cabotegravir. Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.
Synonyms Cabotegravir 13CD5
IUPAC Name (3R,6S)-N-[dideuterio-(2,3,5-trideuterio-4,6-difluorophenyl)(1-13C)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
Related CAS 1051375-10-0 (unlabelled)
Canonical SMILES CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
InChI InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1/i2D,3D,4D,5+1D2
InChI Key WCWSTNLSLKSJPK-YJSYBYGJSA-N

Interested in our Service & Products?
Need detailed information?

USA
  • International: 1-631-504-6093
  • US & Canada (Toll free): 1-844-BOC(262)-0123
  • 45-16 Ramsey Road, Shirley, NY 11967, USA
  • Email: info@bocsci.com
  • Fax: 1-631-614-7828
UK
  • 44-20-3286-1088
  • 85 Great Portland Street, London, W1W 7LT
  • Email: info@bocsci.com
Copyright © 2025 BOC Sciences. All Rights Reserved.
0
Inquiry Basket

No data available, please add!

Delete selectedGo to checkout

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x